RayKnowChina Research Map
Shortlist

JinanShandong First Medical University

First Affiliated Hospital of Shandong First Medical University

山东第一医科大学第一附属医院(山东省千佛山医院)

Listed for 30 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at First Affiliated Hospital of Shandong First Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌6 papers led
  2. Hepatocellular carcinoma肝细胞癌32 papers led
  3. Stomach cancer胃癌26 papers led
  4. Lung cancer肺癌89 papers led4 open trials led
  5. Pancreatic cancer胰腺癌11 papers led
  6. Breast cancer乳腺癌25 papers led
  7. Glioma胶质瘤14 papers led
  8. Hepatoblastoma肝母细胞瘤1 paper led
  9. Retinoblastoma视网膜母细胞瘤0 papers led
  10. Osteosarcoma骨肉瘤3 papers led
  11. Neuroblastoma神经母细胞瘤1 paper led
  12. Multiple myeloma多发性骨髓瘤2 papers led
  13. Lymphoma淋巴瘤6 papers led
  14. Haemophilia A血友病 A2 papers led
  15. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
  16. Myasthenia gravis重症肌无力11 papers led
  17. Moyamoya disease烟雾病3 papers led
  18. Coronary heart disease冠心病8 papers led
  19. Congenital heart disease先天性心脏病5 papers led
  20. Scoliosis脊柱侧弯3 papers led
  21. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎4 papers led
  22. Takayasu arteritis大动脉炎1 paper led
  23. Idiopathic pulmonary fibrosis特发性肺纤维化0 papers led
  24. Lymphangioleiomyomatosis肺淋巴管平滑肌瘤病1 paper led
  25. Amyotrophic lateral sclerosis肌萎缩侧索硬化症2 papers led
  26. Fabry disease法布雷病1 paper led
  27. IgA nephropathyIgA 肾病1 paper led
  28. Gaucher disease戈谢病0 papers led
  29. Osteogenesis imperfecta成骨不全症1 paper led
  30. Hereditary angioedema遗传性血管性水肿0 papers led

Not listed for: Nasopharyngeal carcinoma, Chordoma, Gastrointestinal stromal tumour, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Wilson disease, Biliary atresia, Hepatic echinococcosis, Spinal muscular atrophy, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, Niemann–Pick disease type C, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 6 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 2220232024: 0020242025: 222025

6 hospitals in Jinan for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImmunotherapyNeoadjuvant & combined treatmentMolecular markers & genomics
Departments in papersMedical oncologyGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)
Papers it led6
  1. Efficacy and safety of postoperative radiotherapy in locally advanced esophageal squamous cell carcinoma patients with pathologic incomplete response after neoadjuvant immunochemotherapy: a retrospective cohort study.2025Frontiers in immunologyFree full text
  2. The efficacy and safety of adjuvant immunotherapy after neoadjuvant immunotherapy combined with chemotherapy in locally advanced resectable esophageal squamous cell carcinoma: a real-world study.2025Frontiers in immunologyFree full text
  3. RNF106 aggravates esophageal squamous cell carcinoma progression through LATS2/YAP axis.2023Archives of biochemistry and biophysics
  4. Immune checkpoint inhibitor induced colitis and arthritis: A case report.2023MedicineFree full text
  5. Clinicopathological and Prognostic Significance of SMYD3 in Human Cancers: A Systematic Review and Meta-analysis.2022Genetic testing and molecular biomarkers
  6. Upregulation of miR-1269 Contributes to the Progression of Esophageal Squamous Cell Cancer Cells and Is Associated With Poor Prognosis.2021Technology in cancer research & treatmentFree full text
All its trials on ClinicalTrials.gov, any status3
  1. A Trial of CMNa Combined With Preoperatie Concurrent Chemoradiotherapy for Locally Advanced ESCCTerminatedNCT02721550Study sitePhase 4Start 2016-08
  2. A Trial of CMNa Combined With Concurrent Chemoradiotherapy for Locally Recurrent ESCCTerminatedNCT02721576Study sitePhase 4Start 2016-07
  3. A Trial of CMNa Combined With Definitive Concurrent Chemoradiotherapy for Locally Advanced ESCCCompletedNCT02721563Study sitePhase 4Start 2016-02
More papers found outside PubMed (not counted)8
  1. Adjuvant therapy after neoadjuvant immunotherapy combined with chemotherapy in locally advanced resectable esophageal squamous cell carcinoma: A retrospective study study.2025Journal of Clinical Oncologyarticle
  2. Failure patterns and the value of postoperative adjuvant radiotherapy in esophageal squamous cell carcinoma patients treated with neoadjuvant immunotherapy combined with chemotherapy.2025Journal of Clinical Oncologyarticle
  3. The efficacy and safety of adjuvant immunotherapy after neoadjuvant immunotherapy combined with chemotherapy in locally advanced resectable esophageal squamous cell carcinoma: A real-world study.2025Journal of Clinical Oncologyarticle
  4. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  5. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  6. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  7. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  8. Additional file 6 of Silencing of histone deacetylase 3 suppresses the development of esophageal squamous cell carcinoma through regulation of miR-494-mediated TGIF12022Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 32 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
32
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 6620222023: 111120232024: 6620242025: 442025

6 hospitals in Jinan for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsImaging, AI & early detection
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicinePathology / laboratory medicineMedical oncology
Papers it led32
  1. Radiomic Model Based on Multisequence MRI to Preoperative Predict Ki-67 Expression in Hepatocellular Carcinoma.2026Academic radiology
  2. Lightweight Spectral-MLP for Hyperspectral Differentiation of Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma.2026Journal of biophotonics
  3. Efficacy and safety analysis of transarterial chemoembolization combined with tyrosine kinase inhibitors and immune checkpoint inhibitors with or without microwave ablation for unresectable hepatocellular carcinoma: a retrospective, multice2025Frontiers in immunologyFree full text
  4. Comparative diagnostic efficacy of 18F-FDG and FAPI PET/CT in primary liver cancers: A systematic review and meta-analysis.2025Journal of cancer research and therapeutics
  5. Characterization of T-Cell Receptor Profiles Predicts Survival Situation in Patients with Hepatocellular Carcinoma.2025Technology in cancer research & treatmentFree full text
  6. Phthalate exposure and hepatocellular carcinoma: Unraveling mechanisms through network toxicology.2025Toxicology
  7. A Meta-Analysis of MiRNA-497 and Prognosis of Hepatocellular Carcinoma.2024Canadian journal of gastroenterology & hepatologyFree full text
  8. Clinical outcomes of percutaneous microwave ablation for pulmonary oligometastases from hepatocellular carcinoma: a retrospective, multicenter study.2024Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  9. Is intravoxel incoherent motion magnetic resonance imaging useful for predicting hepatocellular cancer recurrence and invasion of the peritumoral zone after transarterial chemoembolization?2024Journal of cancer research and therapeutics
  10. Exosome-derived circUPF2 enhances resistance to targeted therapy by redeploying ferroptosis sensitivity in hepatocellular carcinoma.2024Journal of nanobiotechnologyFree full text
  11. Camptothecin enhances the anti-tumor effect of low-dose apatinib combined with PD-1 inhibitor on hepatocellular carcinoma.2024Scientific reportsFree full text
  12. High throughput sequencing reveals alterations in B cell receptor repertoires associated with the progression of hepatic cirrhosis to hepatocellular carcinoma.2024Tumori
  13. The lipid peroxidation-derived DNA adduct γ-OHPdG as a diagnostic and prognostic biomarker in hepatocellular carcinoma.2023AgingFree full text
  14. circFAM134B is a key factor regulating reticulophagy-mediated ferroptosis in hepatocellular carcinoma.2023Cell cycle (Georgetown, Tex.)Free full text
  15. Exosomal circTGFBR2 promotes hepatocellular carcinoma progression via enhancing ATG5 mediated protective autophagy.2023Cell death & diseaseFree full text
  16. ZNF8-miR-552-5p Axis Modulates ACSL4-Mediated Ferroptosis in Hepatocellular Carcinoma.2023DNA and cell biology
  17. Iron accumulation and lipid peroxidation: implication of ferroptosis in hepatocellular carcinoma.2023Frontiers in endocrinologyFree full text
  18. Clinical and prognostic significance of CCPG1 in hepatocellular carcinoma.2023General physiology and biophysics
  19. Significant response to transarterial chemoembolization combined with PD-1 inhibitor and apatinib for advanced intrahepatic cholangiocarcinoma: A case report and literature review.2023Journal of cancer research and therapeutics
  20. Transmembrane protein 147, as a potential Sorafenib target, could expedite cell cycle process and confer adverse prognosis in hepatocellular carcinoma.2023Molecular carcinogenesis
  21. Camptothecin improves sorafenib sensitivity by inhibiting Nrf2‑ARE pathway in hepatocellular carcinoma.2023Oncology reportsFree full text
  22. DNA damage repair-related gene signature for identifying the immune status and predicting the prognosis of hepatocellular carcinoma.2023Scientific reportsFree full text
  23. Laparoscopic versus open surgery for hepatic caudate lobectomy: a retrospective study.2023Surgical endoscopy
  24. Natural history of decompensated cirrhosis with serum hepatitis B DNA < 2000 IU/mL: a retrospective study.2022BMC gastroenterologyFree full text
  25. Targeting FAM134B-mediated reticulophagy activates sorafenib-induced ferroptosis in hepatocellular carcinoma.2022Biochemical and biophysical research communications
  26. IGF2BP3-NRF2 axis regulates ferroptosis in hepatocellular carcinoma.2022Biochemical and biophysical research communications
  27. Depleting circ_0088364 restrained cell growth and motility of human hepatocellular carcinoma via circ_0088364-miR-1270-COL4A1 ceRNA pathway.2022Cell cycle (Georgetown, Tex.)Free full text
  28. The deubiquitinase USP7 regulates oxidative stress through stabilization of HO-1.2022Oncogene
  29. Highly expressed FAM189B predicts poor prognosis in hepatocellular carcinoma.2022Pathology oncology research : PORFree full text
  30. RNA binding protein DAZAP1 promotes HCC progression and regulates ferroptosis by interacting with SLC7A11 mRNA.2021Experimental cell research
  31. Determination of risk factors for fever after transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma.2021MedicineFree full text
  32. The clinical significance of microvascular invasion in the surgical planning and postoperative sequential treatment in hepatocellular carcinoma.2021Scientific reportsFree full text
All its trials on ClinicalTrials.gov, any status3
  1. A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.Status unknownNCT06205732Lead sponsorStart 2024-01
  2. Study on the Efficacy and Safety of Conversion Therapy in Patients With Initially Unresectable Hepatocellular CarcinomaStatus unknownNCT06365034Lead sponsorStart 2024-03
  3. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular CarcinomaActive, not recruitingNCT04194775Study sitePhase 3Start 2019-12

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 26 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.3%.

Papers led
26
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 2220212022: 3320222023: 6620232024: 101020242025: 332025

7 hospitals in Jinan for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    Phase
    Phase 3
    Started
    2026-12
    Posted
    Registry
    NCT07789184

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an

  2. Recruiting
    The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure
    Phase
    N/A
    Started
    2023-12
    Posted
    Registry
    NCT06081647

    Age 18 years to 60 years (registered criteria)

    Led by Renji Hospital; 7 listed hospitals as study sitesHangzhou, Jinan, Nanchang, Nanjing, Shanghai

  3. Enrolling by invitation
    An Artificial Intelligence Model for Aiding Claudin18.2 Expression Diagnosis in Gastric Adenocarcinoma
    Phase
    Not given
    Started
    2025-10
    Posted
    Registry
    NCT07274579

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang Hospital; 1 listed hospital as study siteGuangzhou, Jinan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImmunotherapy & targeted drugsChemotherapy & combined treatmentImaging & AI
Departments in papersSurgery (general/hepatobiliary/pancreatic)Medical oncologyPathology / laboratory medicineGastroenterology / hepatology

Over half of these papers are lab or animal studies.

Papers it led26
  1. Nanozymes induced Z-scheme Mn-BiVO4/Au/Bi2S3 heterostructure photoelectrochemical signal amplification for CA72-4 detection.2026Biosensors & bioelectronics
  2. Targeting drug-tolerant persister cells to overcome resistance in HER2-positive gastric cancer.2026Critical reviews in oncology/hematology
  3. Mendelian Randomization and Transcriptome Data Analysis Reveal Bidirectional Causal Relationships and Mechanisms between Type 2 Diabetes and Gastric Cancer.2025Current medicinal chemistry
  4. Analysis of shared pathogenic mechanisms and drug targets in myocardial infarction and gastric cancer based on transcriptomics and machine learning.2025Frontiers in immunologyFree full text
  5. Exploring the regulatory mechanisms of paraptosis-related prognostic genes in gastric cancer using single-cell sequencing and transcriptome analysis.2025Scientific reportsFree full text
  6. Neoadjuvant immunotherapy improves outcomes for resectable gastroesophageal junction cancer: A systematic review and meta-analysis.2024Cancer medicineFree full text
  7. Circular RNA Circ_0001322 inhibits gastric cancer progression by modulating the miR-1264/QKI axis and suppressing the Hedgehog pathway.2024Cellular and molecular biology (Noisy-le-Grand, France)
  8. Nomogram for predicting overall survival after curative gastrectomy using inflammatory, nutritional and pathological factors.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  9. Gentiopicroside inhibits the progression of gastric cancer through modulating EGFR/PI3K/AKT signaling pathway.2024European journal of medical researchFree full text
  10. Hepatoid adenocarcinoma of the stomach with ideal response to neoadjuvant chemo-immunotherapy: a case report.2024Frontiers in immunologyFree full text
  11. Prognostic relevance of prognostic nutritional indices in gastric or gastro-esophageal junction cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.2024Frontiers in immunologyFree full text
  12. Immunoneoadjuvant therapy with immune checkpoint inhibitors of gastric cancer: an emerging exemplification : Immunoneoadjuvant therapy of gastric cancer.2024Investigational new drugs
  13. Efficacy and safety of neoadjuvant therapy in gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis.2024Journal of cancer research and therapeutics
  14. The E3 ligase TRIM7 suppresses the tumorigenesis of gastric cancer by targeting SLC7A11.2024Scientific reportsFree full text
  15. Bile acids inhibit ferroptosis sensitivity through activating farnesoid X receptor in gastric cancer cells.2024World journal of gastroenterologyFree full text
  16. DSC2 suppresses the growth of gastric cancer through the inhibition of nuclear translocation of γ-catenin and PTEN/PI3K/AKT signaling pathway.2023AgingFree full text
  17. A Novel Scoring System in Predicting Prognosis After Adjuvant FOLFOX Chemotherapy in Gastric Cancer.2023Cancer biotherapy & radiopharmaceuticals
  18. circSLC4A7 accelerates stemness and progression of gastric cancer by interacting with HSP90 to activate NOTCH1 signaling pathway.2023Cell death & diseaseFree full text
  19. Microdissection of cancer-associated fibroblast infiltration subtypes unveils the secreted SERPINE2 contributing to immunosuppressive microenvironment and immuotherapeutic resistance in gastric cancer: A large-scale study integrating bulk a2023Computers in biology and medicine
  20. Pseudoprogression during immunotherapy for gastric adenocarcinoma: A case report and literature review.2023Journal of cancer research and therapeutics
  21. Huntingtin-associated protein 1 is a potential tumor suppressor for gastric cancer.2023Molecular biology reports
  22. PADI4 promotes epithelial-mesenchymal transition(EMT) in gastric cancer via the upregulation of interleukin 8.2022BMC gastroenterologyFree full text
  23. PRDX3 promotes resistance to cisplatin in gastric cancer cells.2022Journal of cancer research and therapeutics
  24. Investigating the effect of ARHGEF10L gene on tumor growth in gastric cancer in a nude mouse model using quantitative MRI parameters.2022Journal of cancer research and therapeutics
  25. MicroRNAs are involved in the development and progression of gastric cancer.2021Acta pharmacologica SinicaFree full text
  26. Neoadjuvant chemoradiotherapy plus postoperative adjuvant XELOX chemotherapy versus postoperative adjuvant chemotherapy with XELOX regimen for local advanced gastric cancer-A randomized, controlled study.2021The British journal of radiologyRCTFree full text
All its trials on ClinicalTrials.gov, any status6
  1. Effect of Precise Grip Strength Training on PICC Catheter-Related Thrombosis in Cancer PatientsCompletedNCT05638048Lead (inferred)N/AStart 2022-07
  2. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion TherapyRecruitingNCT07789184Study sitePhase 3Start 2026-12
  3. An Artificial Intelligence Model for Aiding Claudin18.2 Expression Diagnosis in Gastric AdenocarcinomaEnrolling by invitationNCT07274579Study siteStart 2025-10
  4. The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy ProcedureRecruitingNCT06081647Study siteN/AStart 2023-12
  5. First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric CancerActive, not recruitingNCT05586061Study sitePhase 2Start 2023-02
  6. Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior ImmunotherapyActive, not recruitingNCT05585580Study sitePhase 2Start 2023-03

Run the PubMed searchClinicalTrials.gov

Cancer

Lung cancer

肺癌

Led 89 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.4%.

Papers led
89
2021–2025
Trials led
11
any status, ClinicalTrials.gov
Open trials led
4
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 111120212022: 131320222023: 282820232024: 191920242025: 17172025

9 hospitals in Jinan for lung cancer251 hospitals in China for lung cancer

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance
    Phase
    Phase 3
    Started
    2023-09
    Posted
    Registry
    NCT06043973

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Shandong First Medical UniversityJinan

  2. Recruiting
    Adebelizumab Combined With Chemotherapy and Radiotherapy Treat ES-SCLC
    Phase
    Phase 2
    Started
    2023-10
    Posted
    Registry
    NCT06125041

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Shandong First Medical UniversityJinan

  3. Recruiting
    Patient's Whole Process Follow-up Management(HOPE-1)
    Phase
    Not given
    Started
    2022-05
    Posted
    Registry
    NCT05339568

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Shandong First Medical UniversityJinan

  4. Enrolling by invitation
    Efficacy and Safety of Sintilimab Combined with Platinum-containing Double-agent Chemotherapy in First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Elderly Patients
    Phase
    Not given
    Started
    2025-03
    Posted
    Registry
    NCT06883136

    Age 60 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Shandong First Medical UniversityJinan

  5. Recruiting
    Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
    Phase
    Not given
    Started
    2025-02
    Posted
    Registry
    NCT06809764

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 30 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Wuhan, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyRadiology / nuclear medicinePathology / laboratory medicineRadiation oncology
Papers it led89
  1. Local control treatment for pulmonary metastases of colorectal cancer.2026Critical reviews in oncology/hematology
  2. Microwave Ablation Combined with Flt3L Provokes Tumor-Specific Memory CD8+ T Cells-Mediated Antitumor Immunity in Response to PD-1 Blockade.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  3. Overdiagnosis and overtreatment of ground-glass nodule-like lung cancer.2025Asia-Pacific journal of clinical oncology
  4. Tumor treating fields enhance anti-PD therapy by improving CCL2/8 and CXCL9/CXCL10 expression through inducing immunogenic cell death in NSCLC models.2025BMC cancerFree full text
  5. Glimepiride overcomes acquired resistance to EGFR TKIs in lung cancer via the AMPK/ERK/MMP7 signaling pathway.2025Biochemical pharmacology
  6. Microwave ablation combined with immune checkpoint inhibitor enhanced the antitumor immune activation and memory in rechallenged tumor mouse model.2025Cancer immunology, immunotherapy : CIIFree full text
  7. Therapeutic targeting of cGAS-STING pathway in lung cancer.2025Cell biology international
  8. Clinical efficacy and safety of immune checkpoint inhibitors plus anlotinib as secondline or subsequent therapy in extensive stage small cell lung cancer: a retrospective study.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  9. Complement Factor H Promotes the Growth of Lung Adenocarcinoma Cells through the JAK2/STAT3 Signaling Pathway.2025Current cancer drug targets
  10. Discovery of Multiple Effects of Reactive Oxygen Species on Lung Adenocarcinoma at the Single-cell and Bulk Tissue Levels.2025Current medicinal chemistry
  11. Rare recurrent multiple pulmonary sclerosing pneumocytoma with sarcomatoid features: A case report and literature review.2025Journal of cancer research and therapeutics
  12. Construction and application of a mortality risk prediction model for patients with lung squamous cell carcinoma: A competing risk analysis.2025Journal of cancer research and therapeutics
  13. Effectiveness and safety of percutaneous microwave ablation and radiofrequency ablation in the treatment of pulmonary metastasis: A systematic review and meta-analysis.2025Journal of cancer research and therapeutics
  14. Microwave ablation combined with third-generation epidermal growth factor receptor-tyrosine kinase inhibitor treatment in EGFR -mutant advanced non-small cell lung cancer.2025Journal of cancer research and therapeutics
  15. Largest dimension of ground-glass nodule-like lung cancer: Comparison of computed tomography imaging and resected pathological specimens.2025Journal of cancer research and therapeutics
  16. Identifying circRNA-miRNA-mRNA Networks Associated with Osimertinib Resistance in Lung Adenocarcinoma by Analyzing Microarray Datasets.2025Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
  17. Prediction model for growth trends of subpleural subsolid nodules using CT radiomics and radiological features.2025Scientific reportsFree full text
  18. Predicting PD-L1 status in NSCLC patients using deep learning radiomics based on CT images.2025Scientific reportsFree full text
  19. The Evaluation of Urinary HE4, CEA, ProGRP, CYFRA 21-1 and NSE in the Diagnosis of Lung Cancer.2024Annals of clinical and laboratory science
  20. Effect of immune checkpoint inhibitors at different treatment time periods on prognosis of patients with extensive-stage small-cell lung cancer.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  21. Effect of Sequence of Radiotherapy Combined With Immunotherapy on the Incidence of Pneumonitis in Patients With Lung Cancer: A Systematic Review and Network Meta-Analysis.2024Clinical lung cancer
  22. The Relationship between Quantitative Parameters of Dual-energy CT and HIF-1α Expression in Non-Small Cell Lung Cancer.2024Current medical imaging
  23. A review of natural products targeting tumor immune microenvironments for the treatment of lung cancer.2024Frontiers in immunologyFree full text
  24. Hydrodissection technique for pain relief during peri-microwave ablation in patients with subpleural non-small cell lung cancers.2024International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  25. The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer.2024Investigational new drugsFree full text
  26. Successful treatment of epidermal growth factor receptor exon 19 deletion non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: A case report.2024Journal of cancer research and therapeutics
  27. Dihydroartemisinin ameliorates skeletal muscle atrophy in the lung cancer cachexia mouse model.2024Journal of cancer research and therapeutics
  28. Application of computed tomography-based radiomics analysis combined with lung cancer serum tumor markers in the identification of lung squamous cell carcinoma and lung adenocarcinoma.2024Journal of cancer research and therapeutics
  29. Guidelines for power and time variables for microwave ablation in porcine lung in vitro.2024Journal of cancer research and therapeutics
  30. Stem-like CD8 T cells in stage I lung adenocarcinoma as a prognostic biomarker: A preliminary study.2024Journal of cancer research and therapeutics
  31. Enhanced recovery after surgery for microwave ablation of lung tumors: Icing on the cake.2024Journal of cancer research and therapeutics
  32. Identifying Pathological Subtypes of Brain Metastasis from Lung Cancer Using MRI-Based Deep Learning Approach: A Multicenter Study.2024Journal of imaging informatics in medicineFree full text
  33. Chemoradiotherapy Combined with Immunotherapy in Stage III Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Efficacy and Safety Outcomes.2024Oncology
  34. Dissociated response and treatment outcome with immune checkpoint blockade in advanced cancer.2024Scientific reportsFree full text
  35. Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC.2024Scientific reportsFree full text
  36. Dynamic prediction of lung cancer suicide risk based on meteorological factors and clinical characteristics:A landmarking analysis approach.2024Social science & medicine (1982)
  37. Safety and efficacy of percutaneous biopsy and microwave ablation in patients with pulmonary nodules on antithrombotic therapy: A study with rivaroxaban bridging.2024Thoracic cancerFree full text
  38. Differentiation of Lung Metastases Originated From Different Primary Tumors Using Radiomics Features Based on CT Imaging.2023Academic radiologyRCT
  39. Association between quantitative spectral CT parameters, Ki-67 expression, and invasiveness in lung adenocarcinoma manifesting as ground-glass nodules.2023Acta radiologica (Stockholm, Sweden : 1987)
  40. Image-guided thermal ablation for patients with epidermal growth factor receptor-mutant nonsmall cell lung cancer.2023Asia-Pacific journal of clinical oncology
  41. Local thermal ablative therapies for extracranial oligometastatic disease of non-small-cell lung cancer.2023Asia-Pacific journal of clinical oncology
  42. Salidroside regulates tumor microenvironment of non-small cell lung cancer via Hsp70/Stub1/Foxp3 pathway in Tregs.2023BMC cancerFree full text
  43. Effect of oxycodone combined with ultrasound-guided thoracic paravertebral nerve block on postoperative analgesia in patients with lung cancer undergoing thoracoscopic surgery: protocol for a randomised controlled study.2023BMJ openFree full text
  44. Serum ferritin level is an effective prognostic factor for lung cancer immunotherapy.2023Cancer biology & therapyFree full text
  45. Orthogonal threading-through-β-sheet design of lung cancer EGFR extracellular domain-derived peptidic mimotopes binding to anti-EGFR antibody.2023Chemical biology & drug design
  46. Correlation Between Quantitative Spectral CT Parameters and Ki-67 Expression in Lung Adenocarcinomas Manifesting as Ground-glass Nodules.2023Current medical imaging
  47. A prognostic model for predicting progression-free survival in patients with advanced non-small cell lung cancer after image-guided microwave ablation plus chemotherapy.2023European radiologyRCTFree full text
  48. Facilitating combined biopsy and percutaneous microwave ablation of pulmonary ground-glass opacities using lipiodol localisation.2023European radiology
  49. Potential biomarkers for predicting immune response and outcomes in lung cancer patients undergoing thermal ablation.2023Frontiers in immunologyFree full text
  50. Impact of endogenous glucocorticoid on response to immune checkpoint blockade in patients with advanced cancer.2023Frontiers in immunologyFree full text
  51. T lymphocyte cell: A pivotal player in lung cancer.2023Frontiers in immunologyFree full text
  52. Exploration of the Long Noncoding RNAs Involved in the Crosstalk between M2 Macrophages and Tumor Metabolism in Lung Cancer.2023Genetics researchFree full text
  53. Early enlarging cavitation after percutaneous microwave ablation of primary lung cancer.2023International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  54. Synchronous computed tomography-guided percutaneous biopsy and microwave ablation for highly suspicious malignant lung ground-glass opacities adjacent to mediastinum.2023International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  55. Changes in the pulmonary function of CT-guided microwave ablation for patients with malignant lung tumors.2023Journal of cancer research and therapeutics
  56. Lung microwave ablation: Post-procedure imaging features and evolution of pulmonary ground-glass nodule-like lung cancer.2023Journal of cancer research and therapeutics
  57. Microwave ablation for the treatment of peripheral ground-glass nodule-like lung cancer: Long-term results from a multi-center study.2023Journal of cancer research and therapeutics
  58. Immunotherapy for early-stage non-small cell lung cancer: A system review.2023Journal of cancer research and therapeutics
  59. The safety and feasibility of three-dimensional visualization planning system for CT-guided microwave ablation of stage I NSCLC (diameter ≤2.5 cm): A pilot study.2023Journal of cancer research and therapeutics
  60. Progress in the knowledge on the transformation of lung adenocarcinoma to small-cell lung cancer.2023Journal of cancer research and therapeutics
  61. SPACES: Our team's experience in lung tumor microwave ablation.2023Journal of cancer research and therapeutics
  62. Deep Learning With an Attention Mechanism for Differentiating the Origin of Brain Metastasis Using MR images.2023Journal of magnetic resonance imaging : JMRI
  63. Microwave ablation with a blunt-tip antenna for pulmonary ground-glass nodules: a retrospective, multicenter, case-control study.2023La Radiologia medicaFree full text
  64. Tuberous sclerosis complex associated lymphangioleiomyomatosis.2023QJM : monthly journal of the Association of PhysiciansFree full text
  65. Issues and prospects of image-guided thermal ablation in the treatment of primary and metastatic lung tumors.2023Thoracic cancerFree full text
  66. PD-L1 heterogeneity in patients with non-small cell lung cancer.2022Asia-Pacific journal of clinical oncology
  67. Opposing roles of ZEB1 in the cytoplasm and nucleus control cytoskeletal assembly and YAP1 activity.2022Cell reports
  68. Prognostic Profiling of the EMT-Associated and Immunity-Related LncRNAs in Lung Squamous Cell Carcinomas.2022CellsFree full text
  69. Machine Learning-Based Radiomics for Prediction of Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma.2022Disease markersFree full text
  70. Microwave ablation treatment for medically inoperable stage I non-small cell lung cancers: long-term results.2022European radiology
  71. Computed tomography findings, associated factors, and management of pulmonary nodules in 54,326 healthy individuals.2022Journal of cancer research and therapeutics
  72. Microwave ablation of the lung: Comparison of 19G with 14G and 16G microwave antennas in ex vivo porcine lung.2022Journal of cancer research and therapeutics
  73. Hypophysitis: A rare but noteworthy immune-related adverse event secondary to camrelizumab therapy.2022Journal of cancer research and therapeutics
  74. Clinical practice guidelines on image-guided thermal ablation of primary and metastatic lung tumors (2022 edition).2022Journal of cancer research and therapeutics
  75. Microwave ablation of non-small cell lung cancer tumors changes plasma levels of cytokines IL-2 and IFN-γ.2022Journal of cancer research and therapeutics
  76. Recent advances in nonsurgical treatment of pulmonary ground-glass nodules.2022Journal of cancer research and therapeutics
  77. Establishment and Validation of a Nomogram Based on Negative Lymph Nodes to Predict Survival in Postoperative Patients with non-Small Cell Lung Cancer.2022Technology in cancer research & treatmentFree full text
  78. Safety and efficacy of microwave ablation for lung cancer adjacent to the interlobar fissure.2022Thoracic cancerFree full text
  79. Identification of potential target genes of non-small cell lung cancer in response to resveratrol treatment by bioinformatics analysis.2021AgingFree full text
  80. Multicentre study of microwave ablation for pulmonary oligorecurrence after radical resection of non-small-cell lung cancer.2021British journal of cancerFree full text
  81. Identification of a prognostic immune-related signature for small cell lung cancer.2021Cancer medicineFree full text
  82. Could concurrent biopsy and microwave ablation be reliable? Concordance between frozen section examination and final pathology in CT-guided biopsy of lung cancer.2021International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  83. Prediction of risk of suicide death among lung cancer patients after the cancer diagnosis.2021Journal of affective disorders
  84. Effects of CT images at different reconstruction energies on radiotherapy planning of patients diagnosed with nonsmall cell lung cancer.2021Journal of cancer research and therapeutics
  85. Expert consensus on thermal ablation therapy of pulmonary subsolid nodules (2021 Edition).2021Journal of cancer research and therapeutics
  86. Computed tomography-guided percutaneous microwave ablation for pulmonary multiple ground-glass opacities.2021Journal of cancer research and therapeutics
  87. Comparison of Multi-Gene Testing Data Between Fresh and Formalin-Fixed Specimens From Core Needle Biopsy in Patients With NSCLC.2021Pathology oncology research : PORFree full text
  88. Zeb1 induces immune checkpoints to form an immunosuppressive envelope around invading cancer cells.2021Science advancesFree full text
  89. CT-guided microwave ablation in patients with lung metastases from breast cancer.2021Thoracic cancerFree full text
Chinese-language papers (not in the count)3
  1. [Research Progress on Interleukin-6 in Screening and Prognosis of Patients 
with Non-small Cell Lung Cancer].2025Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  2. [Expert Consensus for Thermal Ablation of Pulmonary Subsolid Nodules (2021 Edition)].2021Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  3. [Problems and prospects of image-guided thermal ablation in the treatment of primary and metastatic lung tumors].2021Zhonghua nei ke za zhi
All its trials on ClinicalTrials.gov, any status16
  1. Efficacy and Safety of Sintilimab Combined with Platinum-containing Double-agent Chemotherapy in First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Elderly PatientsEnrolling by invitationNCT06883136Lead sponsorStart 2025-03
  2. Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung CanceRecruitingNCT06043973Lead sponsorPhase 3Start 2023-09
  3. Adebelizumab Combined With Chemotherapy and Radiotherapy Treat ES-SCLCRecruitingNCT06125041Lead sponsorPhase 2Start 2023-10
  4. Patient's Whole Process Follow-up Management(HOPE-1)RecruitingNCT05339568Lead sponsorStart 2022-05
  5. Efficacy and Safety Study of Medical Thoracoscope Cryotherapy Combined Standard First-line Treatment of Advanced Non-small Cell Lung Cancer and Malignant Pleural EffusionStatus unknownNCT05291403Lead sponsorN/AStart 2022-04
  6. Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung CancerStatus unknownNCT04755738Lead sponsorPhase 2Start 2022-01
  7. Low-dose Radiotherapy Combined With Conventional Fractionated Radiotherapy in Lung Cancer After Immunotherapy ResistanceStatus unknownNCT05906329Lead sponsorN/AStart 2022-12
  8. First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm TrialStatus unknownNCT05648071Lead sponsorPhase 3Start 2021-12
  9. First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With Negative Driver Gene: a Multicenter, Single-Arm TrialStatus unknownNCT05574998Lead sponsorPhase 2Start 2021-02
  10. A Real-World Study of Toripalimab in Chinese Patients With Lung Cancer(THUNDER Study)Status unknownNCT05652712Lead sponsorStart 2019-01
  11. Effect of Precise Grip Strength Training on PICC Catheter-Related Thrombosis in Cancer PatientsCompletedNCT05638048Lead (inferred)N/AStart 2022-07
  12. Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)RecruitingNCT06809764Study siteStart 2025-02
  13. Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung CancerTerminatedNCT06897579Study sitePhase 2Start 2025-04
  14. Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)Active, not recruitingNCT06524427Study siteN/AStart 2020-08
  15. A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) PatientsStatus unknownNCT04237805Study sitePhase 1/Phase 2Start 2016-11
  16. Individualized Adaptive Radiotherapy Based on PET/CT and IMRT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)Status unknownNCT02790190Study sitePhase 3Start 2015-05

Run the PubMed searchClinicalTrials.gov

Cancer

Pancreatic cancer

胰腺癌

Led 11 of the 5,743 English-language PubMed papers on pancreatic cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
11
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 4420222023: 2220232024: 1120242025: 112025

6 hospitals in Jinan for pancreatic cancer192 hospitals in China for pancreatic cancer

No open trial on pancreatic cancer lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)Medical oncologyRheumatology & immunologyRadiology / nuclear medicine
Papers it led11
  1. Recent advances and treatment strategies in liver metastasis of pancreatic neuroendocrine tumors.2025Cancer metastasis reviews
  2. Efficacy and safety of neoadjuvant therapy in gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis.2024Journal of cancer research and therapeutics
  3. Endogenous hyperinsulinemic hypoglycemia: case series and literature review.2023EndocrineFree full text
  4. Identification of methyltransferase modification genes associated with prognosis and immune features of pancreatic adenocarcinoma.2023Molecular and cellular probes
  5. Lutein induces an inhibitory effect on the malignant progression of pancreatic adenocarcinoma by targeting BAG3/cholesterol homeostasis.2022Journal of biochemical and molecular toxicology
  6. Pancreatic intra-arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma: A pilot study.2022Journal of cancer research and therapeutics
  7. The Association between Dietary Protein Intake and the Risk of Pancreatic Cancer: Evidence from 14 Publications.2022Nutrition and cancer
  8. The Role of Myeloid-Derived Suppressor Cells in the Treatment of Pancreatic Cancer.2022Technology in cancer research & treatmentFree full text
  9. Identification of novel candidate biomarkers for pancreatic adenocarcinoma based on TCGA cohort.2021AgingFree full text
  10. Nodules on the Lower Legs With Ankle Joint Pain.2021Gastroenterology
  11. Pancreatic carcinoma presented with panniculitis and polyarthritis: A rare case.2021Journal of cancer research and therapeutics

Run the PubMed searchClinicalTrials.gov

Cancer

Breast cancer

乳腺癌

Led 25 of the 16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025: 0.1%.

Papers led
25
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 5520212022: 5520222023: 5520232024: 5520242025: 552025

8 hospitals in Jinan for breast cancer219 hospitals in China for breast cancer

No open trial on breast cancer lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicineMedical oncologySurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicine
Papers it led25
  1. A deep learning model based on chest CT to predict benign and malignant breast masses and axillary lymph node metastasis.2025Biomolecules & biomedicineFree full text
  2. Hyperspectral Imaging for Benign and Malignant Diagnosis of Breast Tumors.2025Journal of biophotonics
  3. Complete response in a patient with metastatic metaplastic breast cancer treated with immune checkpoint inhibitor and chemotherapy: A case report and a review of the literature.2025Journal of cancer research and therapeutics
  4. Impact of postmastectomy radiotherapy on locoregional recurrence and survival in patients with ypN0 breast cancer after neoadjuvant chemotherapy: A comprehensive meta-analysis and systematic review.2025Journal of cancer research and therapeutics
  5. Predicting molecular subtypes of breast cancer based on multi-parametric MRI dataset using deep learning method.2025Magnetic resonance imaging
  6. Multimodal apparent diffusion MRI model in noninvasive evaluation of breast cancer and Ki-67 expression.2024Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  7. Novel pyroptosis-immune-related lncRNA signature exhibits a distinct immune cell infiltration landscape in breast cancer.2024Frontiers in immunologyFree full text
  8. Non-mass-type ductal carcinoma in situ of the breast on ultrasound: Features and pathological analysis.2024Journal of cancer research and therapeutics
  9. Study on the differential diagnosis of benign and malignant breast lesions using a deep learning model based on multimodal images.2024Journal of cancer research and therapeutics
  10. Deep learning radiomics on grayscale ultrasound images assists in diagnosing benign and malignant of BI-RADS 4 lesions.2024Scientific reportsFree full text
  11. Differentiation of Lung Metastases Originated From Different Primary Tumors Using Radiomics Features Based on CT Imaging.2023Academic radiologyRCT
  12. Evaluation of breast cancer malignancy, prognostic factors and molecular subtypes using a continuous-time random-walk MR diffusion model.2023European journal of radiology
  13. PKCζ phosphorylates VASP to mediate chemotaxis in breast cancer cells.2023Experimental cell research
  14. The role of tumor-infiltrating lymphocytes in triple-negative breast cancer and the research progress of adoptive cell therapy.2023Frontiers in immunologyFree full text
  15. Deep Learning With an Attention Mechanism for Differentiating the Origin of Brain Metastasis Using MR images.2023Journal of magnetic resonance imaging : JMRI
  16. Effects of exercise on inflammatory factors and IGF system in breast cancer survivors: a meta-analysis.2022BMC women's healthFree full text
  17. p53 Missense Mutation is Associated with Immune Cell PD-L1 Expression in Triple-Negative Breast Cancer.2022Cancer investigation
  18. Modality-correlation embedding model for breast tumor diagnosis with mammography and ultrasound images.2022Computers in biology and medicine
  19. The Anti-Breast Cancer Activity of Dihydroartemisinin-5-methylisatin Hybrids Tethered via Different Carbon Spacers.2022Molecules (Basel, Switzerland)Free full text
  20. Postmastectomy Radiotherapy Improves Survival Benefits in De Novo Stage IV Breast Cancer: A Propensity-Score Matched Analysis.2022Technology in cancer research & treatmentFree full text
  21. Mediation of circ_RPPH1 on miR-146b-3p/E2F2 pathway to hinder the growth and metastasis of breast carcinoma cells.2021AgingFree full text
  22. LRSCnet: Local Reference Semantic Code learning for breast tumor classification in ultrasound images.2021Biomedical engineering onlineFree full text
  23. Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.2021Frontiers in immunologyFree full text
  24. Giant epidermal inclusion cyst with infection arising within the breast parenchyma: a case report.2021The Journal of international medical researchFree full text
  25. CT-guided microwave ablation in patients with lung metastases from breast cancer.2021Thoracic cancerFree full text
Chinese-language papers (not in the count)1
  1. [A giant malignant phyllodes tumor of the breast: a case report].2022Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status5
  1. Follow up Study of Crocin on Cardiac Function Protection in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy Based on Color Doppler Ultrasound Combined With Myocardial ZymogramStatus unknownNCT06187818Lead (inferred)Start 2023-09
  2. Effect of Precise Grip Strength Training on PICC Catheter-Related Thrombosis in Cancer PatientsCompletedNCT05638048Lead (inferred)N/AStart 2022-07
  3. Neoadjuvant Effect of Albumin Binding Paclitaxel Compared With Common Paclitaxel in Breast Cancer:an Observational Single Center Study of Clinical Efficacy in Adjuvant ChemotherapyStatus unknownNCT05636644Lead (inferred)Start 2022-11
  4. A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast CancerCompletedNCT05945927Study siteStart 2023-09
  5. GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast CancerCompletedNCT05054751Study sitePhase 3Start 2021-09

Run the PubMed searchClinicalTrials.gov

Cancer

Glioma

胶质瘤

Led 14 of the 7,081 English-language PubMed papers on glioma with an author in mainland China, 2021–2025: 0.2%.

Papers led
14
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 6620232024: 2220242025: 332025

5 hospitals in Jinan for glioma187 hospitals in China for glioma

No open trial on glioma lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgeryRadiology / nuclear medicineNeurology

Over half of these papers are lab or animal studies.

Papers it led14
  1. PDIA3 Inhibition Facilitates Sensitivity of IKE-Induced Ferroptosis via STAT3/LCN2 Axis to Improve Glioblastoma Therapy.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  2. PTBP1 Lactylation Promotes Glioma Stem Cell Maintenance through PFKFB4-Driven Glycolysis.2025Cancer research
  3. PYCR1 expresses in cancer-associated fibroblasts and accelerates the progression of C6 glioblastoma.2025Histology and histopathology
  4. Bioinformatics prediction and experimental verification identify B4GALT1 as a diagnostic biomarker of glioblastoma.2025International journal of biological macromolecules
  5. TRIM56: a promising prognostic immune biomarker for glioma revealed by pan-cancer and single-cell analysis.2024Frontiers in immunologyFree full text
  6. Deep learning models for predicting the survival of patients with medulloblastoma based on a surveillance, epidemiology, and end results analysis.2024Scientific reportsFree full text
  7. Integrated Bioinformatic Analysis of the Correlation of HOXA10 Expression with Survival and Immune Cell Infiltration in Lower Grade Glioma.2023Biochemical genetics
  8. N6-Methyladenosine-modified lncRNA LINREP promotes Glioblastoma progression by recruiting the PTBP1/HuR complex.2023Cell death and differentiationFree full text
  9. Re: Effect of glioma-derived immunoglobulin on biological function of glioma cells: The emerging roles of immunoglobulins in the tumor immune microenvironment.2023European journal of cancer (Oxford, England : 1990)
  10. Discrimination Between Glioblastoma and Solitary Brain Metastasis Using Conventional MRI and Diffusion-Weighted Imaging Based on a Deep Learning Algorithm.2023Journal of digital imagingFree full text
  11. Cytokines/chemokines and immune checkpoint molecules in anti-leucine-rich glioma-inactivated 1 encephalitis.2023Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  12. Using the metabolite alterations monitoring the AEG-1 expression level and cell biological behaviour of U251 cell in vitro.2023PloS oneFree full text
  13. Identification of key genes involved in the recurrence of glioblastoma multiforme using weighted gene co-expression network analysis and differential expression analysis.2021BioengineeredFree full text
  14. Hsa_circ_0001017 inhibits proliferation and metastasis via regulating the let-7g-3p/NDST3 axis in glioma.2021Folia neuropathologica

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led 1 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

4 hospitals in Jinan for hepatoblastoma86 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics
Papers it led1
  1. SOX7 modulates the progression of hepatoblastoma through the regulation of Wnt/β-catenin signaling pathway.2022Journal of cancer research and therapeutics
All its trials on ClinicalTrials.gov, any status1
  1. G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant TumorStatus unknownNCT02933333Study sitePhase 4Start 2016-09

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led no English-language PubMed papers on retinoblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

8 hospitals in Jinan for retinoblastoma176 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 3 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 112025

18 hospitals in Jinan for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

8 hospitals in Jinan for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology
Papers it led1
  1. FTO inhibits oxidative stress by mediating m6A demethylation of Nrf2 to alleviate cerebral ischemia/reperfusion injury.2023Journal of physiology and biochemistry
Earlier papers (2016–2020)1
  1. MiR-424 suppressed viability and invasion by targeting to the DCLK1 in neuroblastoma.2020European review for medical and pharmacological sciences
All its trials on ClinicalTrials.gov, any status1
  1. G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant TumorStatus unknownNCT02933333Study sitePhase 4Start 2016-09

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 2 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.1%.

Papers led
2
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

7 hospitals in Jinan for multiple myeloma175 hospitals in China for multiple myeloma

No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Lymphoma

淋巴瘤

Led 6 of the 3,830 English-language PubMed papers on lymphoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
6
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 0020242025: 332025

4 hospitals in Jinan for lymphoma199 hospitals in China for lymphoma

No open trial on lymphoma lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersPediatricsPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 2 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

3 hospitals in Jinan for haemophilia A132 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Jinan for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 11 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 2.2%.

Papers led
11
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 3320212022: 2220222023: 1120232024: 1120242025: 442025

4 hospitals in Jinan for myasthenia gravis89 hospitals in China for myasthenia gravis

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Posted
    Registry
    NCT06447597

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Wuhan, Xi'an, Zunyi

  2. Recruiting
    A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
    Phase
    Phase 3
    Started
    2021-07
    Posted
    Registry
    NCT04951622

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesCrisis & intensive careAntibodies & diagnosisThymus & thymectomy
Departments in papersNeurology

Over half of these papers are lab or animal studies.

Papers it led11
  1. Phenotypic and functional dysregulations of CD8 + T Cells in myasthenia gravis.2025Clinical and experimental medicineFree full text
  2. Myasthenia gravis with double-seropositive acetylcholine receptor and low-density lipoprotein receptor-related protein 4 antibodies combined with muscle atrophy: a case report and literature review.2025Frontiers in immunologyFree full text
  3. Resveratrol-A Herbal Immunomodulator, Ameliorates Experimental Autoimmune Myasthenia Gravis by Regulating the Foxo1-Foxp3 Pathway.2025Journal of biochemical and molecular toxicology
  4. Diabetes exacerbates myasthenia gravis by enhancing pathological thymic output via the GPR183-7α,25-OHC axis.2025Journal of neuroinflammationFree full text
  5. Dihydroartemisinin ameliorates experimental autoimmune myasthenia gravis by regulating CD4+ T cells and modulating gut microbiota.2024International immunopharmacology
  6. Extracellular vesicles encapsulated with caspase-1 inhibitor ameliorate experimental autoimmune myasthenia gravis through targeting macrophages.2023Journal of controlled release : official journal of the Controlled Release Society
  7. Myasthenia gravis: The pharmacological basis of traditional Chinese medicine for its clinical application.2022BioFactors (Oxford, England)
  8. Diabetes mellitus aggravates humoral immune response in myasthenia gravis by promoting differentiation and activation of circulating Tfh cells.2022Clinical immunology (Orlando, Fla.)
  9. Natural killer cells promote the differentiation of follicular helper T cells instead of inducing apoptosis in myasthenia gravis.2021International immunopharmacology
  10. Prophylactic administration of fingolimod (FTY720) ameliorated experimental autoimmune myasthenia gravis by reducing the number of dendritic cells, follicular T helper cells and antibody-secreting cells.2021International immunopharmacology
  11. Diabetes mellitus exacerbates experimental autoimmune myasthenia gravis via modulating both adaptive and innate immunity.2021Journal of neuroinflammationFree full text
All its trials on ClinicalTrials.gov, any status3
  1. A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.RecruitingNCT06447597Study sitePhase 2/Phase 3Start 2024-07
  2. A Study of Nipocalimab Administered to Adults With Generalized Myasthenia GravisRecruitingNCT04951622Study sitePhase 3Start 2021-07
  3. A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia GravisTerminatedNCT04963270Study sitePhase 3Start 2021-10

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 3 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 0.8%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 112025

1 hospital in Jinan for moyamoya disease47 hospitals in China for moyamoya disease

No open trial on moyamoya disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImaging & blood flowRevascularisation surgeryGenetics
Departments in papersRadiology / nuclear medicinePathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Coronary heart disease

冠心病

Led 8 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 0.2%.

Papers led
8
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 3320222023: 0020232024: 0020242025: 112025

6 hospitals in Jinan for coronary heart disease231 hospitals in China for coronary heart disease

No open trial on coronary heart disease lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine
Papers it led8
  1. C/EBPβ-Lin28a positive feedback loop triggered by C/EBPβ hypomethylation enhances the proliferation and migration of vascular smooth muscle cells in restenosis.2025Chinese medical journalFree full text
  2. Wrist pulse diagnosis of stable coronary heart disease based on acoustics waveforms.2022Computer methods and programs in biomedicine
  3. Recurrent type III Kounis syndrome: coronary artery inflammation assessed by 18F-fluorodeoxyglucose positron emission tomography/computer tomography.2022European heart journal. Cardiovascular Imaging
  4. Multi-trajectories of systolic and diastolic hypertension and coronary heart disease in middle-aged and older adults.2022Frontiers in public healthFree full text
  5. Methylenetetrahydrofolate Reductase Gene Polymorphism C677T is Associated with Increased Risk of Coronary Heart Disease in Chinese Type 2 Diabetic Patients.2021Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
  6. A cohort study on risk factors of high-density lipoprotein cholesterol hypolipidemia among urban Chinese adults.2021Lipids in health and diseaseFree full text
  7. Association of dipeptidyl peptidase IV polymorphism, serum lipid profile, and coronary artery stenosis in patients with coronary artery disease and type 2 diabetes.2021MedicineFree full text
  8. Cardiac cephalalgia closely associated with acute myocardial infarction.2021The American journal of emergency medicine
All its trials on ClinicalTrials.gov, any status4
  1. Modified Dynamic Needle Tip Positioning vs Conventional Long-axis In-plane in Radial Artery CannulationCompletedNCT05687370Lead sponsorN/AStart 2023-01
  2. Hemodynamic Effect of Topical Anesthesia During Induction in Patients Undergoing Cardiac SurgeryCompletedNCT05323786Lead sponsorN/AStart 2022-04
  3. Effect of Topical Anesthesia on Hemodynamics During the Induction Period in Patients Undergo Cardiac Surgery.CompletedNCT04744480Lead sponsorN/AStart 2021-03
  4. Comparison of Dexmedetomidine and Meperidine for the Prevention of Shivering Following Coronary Artery Bypass GraftStatus unknownNCT04735965Lead sponsorPhase 4Start 2021-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital heart disease

先天性心脏病

Led 5 of the 2,604 English-language PubMed papers on congenital heart disease with an author in mainland China, 2021–2025: 0.2%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 1120242025: 222025

4 hospitals in Jinan for congenital heart disease207 hospitals in China for congenital heart disease

No open trial on congenital heart disease lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersNeurologyRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Scoliosis

脊柱侧弯

Led 3 of the 925 English-language PubMed papers on scoliosis with an author in mainland China, 2021–2025: 0.3%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 112025

3 hospitals in Jinan for scoliosis107 hospitals in China for scoliosis

No open trial on scoliosis lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 4 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 1.5%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 0020232024: 0020242025: 002025

5 hospitals in Jinan for anti-NMDA receptor encephalitis124 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurologyNeurosurgery
Papers it led4
  1. Increased formation of neutrophil extracellular traps in patients with anti-N-methyl-d-aspartate receptor encephalitis.2022Frontiers in immunologyFree full text
  2. Coexistence of NMDAR, GAD65, and SOX1 antibody-associated autoimmune encephalitis.2022Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  3. Recurrent anti-AMPA receptor encephalitis associated with thymus cancer.2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  4. Long-term follow-up of a child with anti-AMPA receptor encephalitis.2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 1 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

2 hospitals in Jinan for Takayasu arteritis100 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led no English-language PubMed papers on idiopathic pulmonary fibrosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

8 hospitals in Jinan for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    Phase
    Phase 3
    Started
    2026-09
    Posted
    Registry
    NCT07687459

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status3
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09
  2. A Phase I Study of HW241045 in Healthy SubjectsNot yet recruitingNCT07593690Study sitePhase 1Start 2026-06
  3. A Trial of SHR - 1906 in Healthy SubjectsCompletedNCT04986540Study sitePhase 1Start 2021-08

Run the PubMed searchClinicalTrials.gov

Other diseases

Lymphangioleiomyomatosis

肺淋巴管平滑肌瘤病

Led 1 of the 45 English-language PubMed papers on lymphangioleiomyomatosis with an author in mainland China, 2021–2025: 2.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

2 hospitals in Jinan for lymphangioleiomyomatosis27 hospitals in China for lymphangioleiomyomatosis

No open trial on lymphangioleiomyomatosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Tuberous sclerosis complex associated lymphangioleiomyomatosis.2023QJM : monthly journal of the Association of PhysiciansFree full text

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 2 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

8 hospitals in Jinan for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicineNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led 1 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 1.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

3 hospitals in Jinan for Fabry disease80 hospitals in China for Fabry disease

No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 1 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

9 hospitals in Jinan for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Gaucher disease

戈谢病

Led no English-language PubMed papers on Gaucher disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Jinan for Gaucher disease40 hospitals in China for Gaucher disease

No open trial on Gaucher disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led 1 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Jinan for osteogenesis imperfecta58 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Hereditary angioedema

遗传性血管性水肿

Led no English-language PubMed papers on hereditary angioedema in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Jinan for hereditary angioedema30 hospitals in China for hereditary angioedema

No open trial on hereditary angioedema lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in ChinaCompletedNCT06346899Study siteStart 2024-07

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

山东第一医科大学第一附属医院(山东省千佛山医院)

First Affiliated Hospital of Shandong First Medical University

济南

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Shandong Provincial Qianfoshan Hospital; Qianfoshan Hospital Affiliated to Shandong University; Qianfoshan Hospital; Shandong Qianfoshan Hospital; Qianfoshan Hospital Affiliated with Shandong University; Shandong Qianfoshan Hospital Affiliated With Shandong University; Shandong Qianfoshan Hospital Affiliated to Shandong University; first affiliated hospital of Shandong First medical university

Suggest a correctionDownload the data